<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is an aggressive B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> characterized by typical morphological, immunophenotypic and molecular features </plain></SENT>
<SENT sid="1" pm="."><plain>Gene expression profiling provided a molecular signature of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, but also demonstrated that a subset of aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> nonetheless show a molecular signature of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> ('discrepant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>') </plain></SENT>
<SENT sid="2" pm="."><plain>Given the different treatment of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> we investigated molecular differences within gene expression-defined Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN AND METHODS: We studied <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from 51 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients, comprising 26 with classic Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 17 with atypical Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 8 with 'discrepant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>', by comparative genomic hybridization and gene expression profiling </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Classic and atypical Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (excluding 'discrepant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous. 'Discrepant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and from diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, this category includes <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Pediatric and adult Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are molecularly homogeneous, whereas 'discrepant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>' differ in underlying genetic and clinical features from typical/atypical Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>. 'Discrepant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>' may therefore form a distinct genetic subgroup of aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, which show poor response to multi-agent chemotherapy </plain></SENT>
</text></document>